DXB

0.00%

38.0¢ dimerix limited

Ann: Dimerix presentation at Bioshares Biotech Summit, page-34

First 34 Last

Share
Profile

Follow
UncleFesta

1,572 Posts.

547

14/07/24

16:36

Post #: 74746538
Share

Originally posted by MongooseMan: ↑

The only useful information to come out of this presentation IMO, which everybody seems to have ignored, is the recruitment: 72% of the way towards the first target of 144, means they're only at 104. True target is 286, word on the street is FDA unlikely to accept a trial that's only 50% completed based on proteinuria.
But let's indulge the 144 target for a moment. DXB announced 72nd pt randomised last July. They've managed 32 more in the last 12 months= roughly 2.5 patients per month only. Don't need a calculator, to get the remaining 40 to hit 144 requires another 16 months at the current rate! Then add on 8 more months for the endpoint, takes this to July 2026 just for the interim.
@vintage, you still confident about your prediction you made last month that they'd have the 144 by this Oct/Nov? I thought you said there is a big expansion in trial sites. They're miles behind. How do they justify mid 2025 for the interim based on these facts? I don't think any China hospitals are even open for the trial is that right? Could that be why no China partner yet?
At the current rate, to get the remaining 182 to complete full trial is still 6 years away. Very worrying.
Can't imagine many license partners wanting to show patience and hang around while this trial meanders to the finish line unless there is a seismic improvement in recruitment performance, I'm sure they all have lot of other commercially attractive things going on.

Expand

"Word on the street"
overflowing bucket of crap.
Fes

DXB Price at posting: 49.0¢ Sentiment: Buy Disclosure: Held
Upvote

0 Great analysis

Reply

Top Stories

ACW

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

BUX

Buxton projects new graphite province discovery at WA Narryer play

BCI

BCI reaches close of funding facility for salt-first part of Mardie project

SLS

Solstice Minerals to ramp up drilling campaign at Yarri Gold Project

COD

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

Week 40 Wrap: China's nonsensical stimmy hype wanes (shocking!); HotCopper's picks; oil & inflation

NTI

Neurotech knocked back by FDA as agency declares target condition not rare enough for special status

WCN

White Cliff jumps 24% on 'bonanza grade' copper rock chips at Rae project, Canada

RCE

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

CKA

Cokal upgrades infrastructure for BBM ramp-up in Indonesia

There are more pages in this discussion • 46 more messages in this thread...

First 34 Last

Add DXB (ASX) to my watchlist

(20min delay)
Last 38.0¢		Change 0.000(0.00%)		Mkt cap ! $211.7M

Open	High	Low	Value	Volume
38.0¢	38.0¢	37.0¢	$246.4K	658.0K

Buyers (Bids)

No.	Vol.	Price($)
10	262775	37.0¢

Sellers (Offers)

Price($)	Vol.	No.
38.0¢	32276	2

View Market Depth

No.	Vol.	Price($)
7	195263	0.370
12	1397167	0.365
6	59089	0.360
3	52619	0.355
9	102527	0.350

Price($)	Vol.	No.
0.380	32276	2
0.385	30000	1
0.390	25524	3
0.395	161740	3
0.400	141398	5

Last trade - 16.10pm 04/10/2024 (20 minute delay)

DXB (ASX) Chart

Ann: Dimerix presentation at Bioshares Biotech Summit, page-34

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

Buxton projects new graphite province discovery at WA Narryer play

BCI reaches close of funding facility for salt-first part of Mardie project

Solstice Minerals to ramp up drilling campaign at Yarri Gold Project

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

Week 40 Wrap: China's nonsensical stimmy hype wanes (shocking!); HotCopper's picks; oil & inflation

Neurotech knocked back by FDA as agency declares target condition not rare enough for special status

White Cliff jumps 24% on 'bonanza grade' copper rock chips at Rae project, Canada

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

Cokal upgrades infrastructure for BBM ramp-up in Indonesia

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

Ann: Dimerix presentation at Bioshares Biotech Summit, page-34

Top Stories

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

Buxton projects new graphite province discovery at WA Narryer play

BCI reaches close of funding facility for salt-first part of Mardie project

Solstice Minerals to ramp up drilling campaign at Yarri Gold Project

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

Week 40 Wrap: China's nonsensical stimmy hype wanes (shocking!); HotCopper's picks; oil & inflation

Neurotech knocked back by FDA as agency declares target condition not rare enough for special status

White Cliff jumps 24% on 'bonanza grade' copper rock chips at Rae project, Canada

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

Cokal upgrades infrastructure for BBM ramp-up in Indonesia

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News